Prospective Evaluation of Low-dose Irinotecan and Cyberknife® Stereotactic Body Radiotherapy in the Treatment of Patients With Colorectal Cancer and Limited Liver Metastasis
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with adverse events related to toxicities from concurrent SBRT and irinotecan
3 years
Yes
Arica Hirsch, MD
Study Chair
Advocate Lutheran General Hospital
United States: Institutional Review Board
5443
NCT01847495
May 2013
May 2023
Name | Location |
---|---|
Advocate Lutheran General Hospital | Park Ridge, Illinois 60068 |